{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T11:31:17Z","timestamp":1793532677895,"version":"4.5.0"},"reference-count":89,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1016\/j.eururo.2016.08.003","type":"journal-article","created":{"date-parts":[[2016,8,31]],"date-time":"2016-08-31T02:05:51Z","timestamp":1472609151000},"page":"618-629","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2502,"title":["EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent"],"prefix":"10.1016","volume":"71","author":[{"given":"Nicolas","family":"Mottet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaquim","family":"Bellmunt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Bolla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Briers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus G.","family":"Cumberbatch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"De Santis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Fossati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Gross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann M.","family":"Henry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Joniau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas B.","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malcolm D.","family":"Mason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vsevolod B.","family":"Matveev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul C.","family":"Moldovan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roderick C.N.","family":"van den Bergh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Van den Broeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henk G.","family":"van der Poel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theo H.","family":"van der Kwast","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Rouvi\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivo G.","family":"Schoots","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Wiegel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Cornford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2016.08.003_bib0435","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.eururo.2013.09.046","article-title":"EAU guidelines on prostate cancer: Part 1: Screening, diagnosis, and local treatment with curative intent-update 2013","volume":"65","author":"Heidenreich","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2016.08.003_bib0440","unstructured":"Oxford Centre for Evidence-Based Medicine \u2013 levels of evidence (March 2009). Centre for Evidence-Based Medicine Web site. http:\/\/www.cebm.net\/oxford-centre-evidence-based-medicine-levels-evidence-march-2009\/."},{"key":"10.1016\/j.eururo.2016.08.003_bib0445","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/j.ejca.2013.09.002","article-title":"Recent trends in incidence of five common cancers in 26 European countries since 1988: analysis of the European Cancer Observatory","volume":"51","author":"Arnold","year":"2015","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.eururo.2016.08.003_bib0450","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/CLEP.S16747","article-title":"Risk factors for the onset of prostatic cancer: age, location, and behavioural correlates","volume":"4","author":"Leitzmann","year":"2012","journal-title":"Clin Epidemiol"},{"key":"10.1016\/j.eururo.2016.08.003_bib0455","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1007\/BF03346748","article-title":"Effect of metabolic syndrome and its components on prostate cancer risk: metaanalysis","volume":"36","author":"Esposito","year":"2013","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.eururo.2016.08.003_bib0460","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.juro.2014.06.071","article-title":"Incidence of prostate cancer in hypogonadal men receiving testosterone therapy: observations from 5-year median followup of 3 registries","volume":"193","author":"Haider","year":"2015","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2016.08.003_bib0465","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1002\/pros.22925","article-title":"Prostate cancer risk prediction based on complete prostate cancer family history","volume":"75","author":"Albright","year":"2015","journal-title":"Prostate"},{"key":"10.1016\/j.eururo.2016.08.003_bib0470","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s00345-011-0801-1","article-title":"Familial risk and familial survival in prostate cancer","volume":"30","author":"Hemminki","year":"2012","journal-title":"World J Urol"},{"key":"10.1016\/j.eururo.2016.08.003_bib0475","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.eururo.2014.10.022","article-title":"Effect of BRCA mutations on metastatic relapse and cause-specific survival after radical treatment for localised prostate cancer","volume":"68","author":"Castro","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2016.08.003_bib0480","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1200\/JCO.2012.43.1882","article-title":"Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer","volume":"31","author":"Castro","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2016.08.003_bib0485","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.eururo.2014.01.003","article-title":"Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: results from the initial screening round of the IMPACT study","volume":"66","author":"Bancroft","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2016.08.003_bib0490","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/PAS.0000000000000530","article-title":"The 2014 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma: definition of grading patterns and proposal for a new grading system","volume":"40","author":"Epstein","year":"2016","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.eururo.2016.08.003_bib0495","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1001\/jama.2014.2085","article-title":"Screening for prostate cancer with the prostate-specific antigen test: a review of current evidence","volume":"311","author":"Hayes","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.eururo.2016.08.003_bib0500","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1016\/S0140-6736(14)60525-0","article-title":"Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up","volume":"384","author":"Schr\u00f6der","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2016.08.003_bib0505","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1016\/S0140-6736(12)61611-0","article-title":"The benefits and harms of breast cancer screening: an independent review","volume":"380","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2016.08.003_bib0510","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.juro.2015.07.099","article-title":"Prostate needle biopsy outcomes in the era of the U.S. Preventive Services Task Force recommendation against prostate specific antigen based screening","volume":"195","author":"Banerji","year":"2016","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2016.08.003_bib0515","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.eururo.2014.12.006","article-title":"Opportunistic testing versus organized prostate-specific antigen screening: outcome after 18 years in the Goteborg randomized population-based prostate cancer screening trial","volume":"68","author":"Arnsrud Godtman","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2016.08.003_bib0520","doi-asserted-by":"crossref","first-page":"f2023","DOI":"10.1136\/bmj.f2023","article-title":"Strategy for detection of prostate cancer based on relation between prostate specific antigen at age 40-55 and long term risk of metastasis: case-control study","volume":"346","author":"Vickers","year":"2013","journal-title":"BMJ"},{"key":"10.1016\/j.eururo.2016.08.003_bib0525","doi-asserted-by":"crossref","first-page":"g2296","DOI":"10.1136\/bmj.g2296","article-title":"Influence of blood prostate specific antigen levels at age 60 on benefits and harms of prostate cancer screening: population based cohort study","volume":"348","author":"Carlsson","year":"2014","journal-title":"BMJ"},{"key":"10.1016\/j.eururo.2016.08.003_bib0530","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1093\/annonc\/mdu525","article-title":"Do prostate cancer risk models improve the predictive accuracy of PSA screening?. A meta-analysis","volume":"26","author":"Louie","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eururo.2016.08.003_bib0535","doi-asserted-by":"crossref","first-page":"e404","DOI":"10.1016\/S1470-2045(14)70018-X","article-title":"Management of prostate cancer in older patients: updated recommendations of a working group of the International Society of Geriatric Oncology","volume":"15","author":"Droz","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2016.08.003_bib0540","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1111\/bju.12241","article-title":"Empiric antibiotics for an elevated prostate-specific antigen (PSA) level: a randomised, prospective, controlled multi-institutional trial","volume":"112","author":"Eggener","year":"2013","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2016.08.003_bib0545","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1177\/1756287213513488","article-title":"The Prostate Health Index: a new test for the detection of prostate cancer","volume":"6","author":"Loeb","year":"2014","journal-title":"Ther Adv Urol"},{"key":"10.1016\/j.eururo.2016.08.003_bib0550","doi-asserted-by":"crossref","first-page":"djv095","DOI":"10.1093\/jnci\/djv095","article-title":"Predicting high-grade cancer at ten-core prostate biopsy using four kallikrein markers measured in blood in the ProtecT study","volume":"107","author":"Bryant","year":"2015","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.eururo.2016.08.003_bib0555","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.urology.2007.09.029","article-title":"Optimal approach for prostate cancer detection as initial biopsy: prospective randomized study comparing transperineal versus transrectal systematic 12-core biopsy","volume":"71","author":"Hara","year":"2008","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2016.08.003_bib0560","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/sj.pcan.4500985","article-title":"A prospective randomized comparison of diagnostic efficacy between transperineal and transrectal 12-core prostate biopsy","volume":"11","author":"Takenaka","year":"2008","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.eururo.2016.08.003_bib0565","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/j.eururo.2013.05.049","article-title":"Systematic review of complications of prostate biopsy","volume":"64","author":"Loeb","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2016.08.003_bib0570","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.eururo.2015.01.013","article-title":"Can clinically significant prostate cancer be detected with multiparametric magnetic resonance imaging? A systematic review of the literature","volume":"68","author":"Futterer","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2016.08.003_bib0575","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/j.juro.2014.04.094","article-title":"Magnetic resonance imaging-ultrasound fusion biopsy for prediction of final prostate pathology","volume":"192","author":"Le","year":"2014","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2016.08.003_bib0580","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.eururo.2012.06.004","article-title":"Image-guided prostate biopsy using magnetic resonance imaging-derived targets: a systematic review","volume":"63","author":"Moore","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2016.08.003_bib0585","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1001\/jama.2014.17942","article-title":"Comparison of MR\/ultrasound fusion-guided biopsy with ultrasound-guided biopsy for the diagnosis of prostate cancer","volume":"313","author":"Siddiqui","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.eururo.2016.08.003_bib0590","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.eururo.2014.11.037","article-title":"Magnetic resonance imaging-targeted biopsy may enhance the diagnostic accuracy of significant prostate cancer detection compared to standard transrectal ultrasound-guided biopsy: a systematic review and meta-analysis","volume":"68","author":"Schoots","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2016.08.003_bib0595","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2014.09.013","article-title":"Multiparametric magnetic resonance imaging vs. standard care in men being evaluated for prostate cancer: a randomized study","volume":"33","author":"Panebianco","year":"2015","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2016.08.003_bib0600","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.eururo.2015.03.041","article-title":"A randomized controlled trial to assess and compare the outcomes of two-core prostate biopsy guided by fused magnetic resonance and transrectal ultrasound images and traditional 12-core systematic biopsy","volume":"69","author":"Baco","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2016.08.003_bib0605","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1148\/radiol.14131584","article-title":"Characterization of prostate lesions as benign or malignant at multiparametric MR imaging: comparison of three scoring systems in patients treated with radical prostatectomy","volume":"272","author":"Vache","year":"2014","journal-title":"Radiology"},{"key":"10.1016\/j.eururo.2016.08.003_bib0610","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.eururo.2015.08.038","article-title":"Synopsis of the PI-RADS v2 guidelines for multiparametric prostate magnetic resonance imaging and recommendations for use","volume":"69","author":"Barentsz","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2016.08.003_bib0615","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1097\/MOU.0000000000000157","article-title":"Observational studies and the natural history of screen-detected prostate cancer","volume":"25","author":"Albertsen","year":"2015","journal-title":"Curr Opin Urol"},{"key":"10.1016\/j.eururo.2016.08.003_bib0620","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa1113162","article-title":"Radical prostatectomy versus observation for localized prostate cancer","volume":"367","author":"Wilt","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2016.08.003_bib0625","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1200\/JCO.2010.31.2330","article-title":"Impact of comorbidity on survival among men with localized prostate cancer","volume":"29","author":"Albertsen","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2016.08.003_bib0630","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1002\/jso.23584","article-title":"Active surveillance for clinically localized prostate cancer--a systematic review","volume":"109","author":"Thomsen","year":"2014","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.eururo.2016.08.003_bib0635","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.eururo.2014.10.010","article-title":"Active surveillance for prostate cancer: a systematic review of clinicopathologic variables and biomarkers for risk stratification","volume":"67","author":"Loeb","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2016.08.003_bib0640","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/s00428-014-1668-5","article-title":"Consensus statement with recommendations on active surveillance inclusion criteria and definition of progression in men with localized prostate cancer: the critical role of the pathologist","volume":"465","author":"Montironi","year":"2014","journal-title":"Virchows Arch"},{"key":"10.1016\/j.eururo.2016.08.003_bib0645","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.eururo.2014.10.050","article-title":"Magnetic resonance imaging in active surveillance of prostate cancer: a systematic review","volume":"67","author":"Schoots","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2016.08.003_bib0650","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1200\/JCO.2009.24.2180","article-title":"Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer","volume":"28","author":"Klotz","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2016.08.003_bib0655","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S0022-5347(05)00342-3","article-title":"Validation of a nomogram for prediction of side specific extracapsular extension at radical prostatectomy","volume":"175","author":"Steuber","year":"2006","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2016.08.003_bib0660","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.eururo.2015.07.029","article-title":"Accuracy of magnetic resonance imaging for local staging of prostate cancer: a diagnostic meta-analysis","volume":"70","author":"de Rooij","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2016.08.003_bib0665","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S1470-2045(09)70079-8","article-title":"The surgical learning curve for laparoscopic radical prostatectomy: a retrospective cohort study","volume":"10","author":"Vickers","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2016.08.003_bib0670","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta16410","article-title":"Systematic review and economic modelling of the relative clinical benefit and cost-effectiveness of laparoscopic surgery and robotic surgery for removal of the prostate in men with localised prostate cancer","volume":"16","author":"Ramsay","year":"2012","journal-title":"Health Technol Assess"},{"key":"10.1016\/j.eururo.2016.08.003_bib0675","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.eururo.2011.10.044","article-title":"Updated nomogram predicting lymph node invasion in patients with prostate cancer undergoing extended pelvic lymph node dissection: the essential importance of percentage of positive cores","volume":"61","author":"Briganti","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2016.08.003_bib0680","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.eururo.2006.08.015","article-title":"Complications and other surgical outcomes associated with extended pelvic lymphadenectomy in men with localized prostate cancer","volume":"50","author":"Briganti","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2016.08.003_bib0685","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/S1470-2045(06)70700-8","article-title":"Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy","volume":"7","author":"Messing","year":"2006","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2016.08.003_bib0690","doi-asserted-by":"crossref","first-page":"3939","DOI":"10.1200\/JCO.2013.54.7893","article-title":"Impact of adjuvant radiotherapy on survival of patients with node-positive prostate cancer","volume":"32","author":"Abdollah","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2016.08.003_bib0695","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1056\/NEJMoa1311593","article-title":"Radical prostatectomy or watchful waiting in early prostate cancer","volume":"370","author":"Bill-Axelson","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2016.08.003_bib0700","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1136\/jclinpath-2014-202767","article-title":"Prostate biopsy concordance in a large population-based sample: a Surveillance, Epidemiology and End Results study","volume":"68","author":"Schreiber","year":"2015","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.eururo.2016.08.003_bib0705","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.eururo.2007.10.008","article-title":"Secondary therapy, metastatic progression, and cancer-specific mortality in men with clinically high-risk prostate cancer treated with radical prostatectomy","volume":"53","author":"Yossepowitch","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2016.08.003_bib0710","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1111\/j.1464-410X.2010.09594.x","article-title":"Pathological results and rates of treatment failure in high-risk prostate cancer patients after radical prostatectomy","volume":"107","author":"Walz","year":"2011","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2016.08.003_bib0715","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.eururo.2010.03.001","article-title":"Outcome predictors of radical prostatectomy in patients with prostate-specific antigen greater than 20ng\/ml: a European multi-institutional study of 712 patients","volume":"58","author":"Spahn","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2016.08.003_bib0720","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.eururo.2014.01.020","article-title":"Stratification of high-risk prostate cancer into prognostic categories: a European multi-institutional study","volume":"67","author":"Joniau","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2016.08.003_bib0725","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.eururo.2012.05.045","article-title":"Systematic review and meta-analysis of studies reporting urinary continence recovery after robot-assisted radical prostatectomy","volume":"62","author":"Ficarra","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2016.08.003_bib0730","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.eururo.2015.02.029","article-title":"Urinary incontinence and erectile dysfunction after robotic versus open radical prostatectomy: a prospective, controlled, nonrandomised trial","volume":"68","author":"Haglind","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2016.08.003_bib0735","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/j.ijrobp.2007.11.044","article-title":"Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer","volume":"70","author":"Zelefsky","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.eururo.2016.08.003_bib0740","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1016\/j.ijrobp.2010.01.006","article-title":"Long-term failure patterns and survival in a randomized dose-escalation trial for prostate cancer. Who dies of disease?","volume":"79","author":"Kuban","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.eururo.2016.08.003_bib0745","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1200\/JCO.2009.25.8475","article-title":"Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from proton radiation oncology group\/American College of Radiology 95-09","volume":"28","author":"Zietman","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2016.08.003_bib0750","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.ijrobp.2010.03.049","article-title":"70Gy versus 80Gy in localized prostate cancer: 5-year results of GETUG 06 randomized trial","volume":"80","author":"Beckendorf","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.eururo.2016.08.003_bib0755","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.radonc.2013.09.026","article-title":"Long-term results of the Dutch randomized prostate cancer trial: impact of dose-escalation on local, biochemical, clinical failure, and survival","volume":"110","author":"Heemsbergen","year":"2014","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.eururo.2016.08.003_bib0760","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1001\/jamaoncol.2015.2316","article-title":"Dose-escalated irradiation and overall survival in men with non-metastatic prostate cancer","volume":"1","author":"Kalbasi","year":"2015","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.eururo.2016.08.003_bib0865","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/S1470-2045(16)30102-4","article-title":"CHHiP Investigators. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial","volume":"17","author":"Dearnaley","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2016.08.003_bib0870","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1200\/JCO.2016.67.0448","article-title":"Randomized Phase III Noninferiority Study Comparing Two Radiotherapy Fractionation Schedules in Patients With Low-Risk Prostate Cancer","volume":"34","author":"Lee","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2016.08.003_bib0875","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/S1470-2045(16)30070-5","article-title":"Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial","volume":"17","author":"Incrocci","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2016.08.003_bib0770","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa1012348","article-title":"Radiotherapy and short-term androgen deprivation for localized prostate cancer","volume":"365","author":"Jones","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2016.08.003_bib0775","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/S1470-2045(10)70223-0","article-title":"External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study","volume":"11","author":"Bolla","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2016.08.003_bib0780","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1056\/NEJMoa0810095","article-title":"Duration of androgen suppression in the treatment of prostate cancer","volume":"360","author":"Bolla","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2016.08.003_bib0785","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1016\/j.ijrobp.2004.08.047","article-title":"Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma--long-term results of phase III RTOG 85-31","volume":"61","author":"Pilepich","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.eururo.2016.08.003_bib0790","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1200\/JCO.2014.57.7510","article-title":"Final report of the intergroup randomized study of combined androgen-deprivation therapy plus radiotherapy versus androgen-deprivation therapy alone in locally advanced prostate cancer","volume":"33","author":"Mason","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2016.08.003_bib0795","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/S1470-2045(15)00011-X","article-title":"Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial","volume":"16","author":"Fizazi","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2016.08.003_bib0800","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.ijrobp.2007.04.003","article-title":"An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone\/radiation interactions","volume":"69","author":"Lawton","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.eururo.2016.08.003_bib0805","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1001\/jamaoncol.2015.4350","article-title":"Failure-free survival and radiotherapy in patients with newly diagnosed nonmetastatic prostate cancer: data from patients in the control arm of the STAMPEDE trial","volume":"2","author":"James","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.eururo.2016.08.003_bib0810","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1016\/S0140-6736(12)61253-7","article-title":"Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911)","volume":"380","author":"Bolla","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2016.08.003_bib0815","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.eururo.2014.03.011","article-title":"Adjuvant radiotherapy versus wait-and-see after radical prostatectomy: 10-year follow-up of the ARO 96-02\/AUO AP 09\/95 trial","volume":"66","author":"Wiegel","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2016.08.003_bib0820","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.juro.2008.11.032","article-title":"Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial","volume":"181","author":"Thompson","year":"2009","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2016.08.003_bib0825","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.eururo.2015.10.009","article-title":"Assessing the optimal timing for early salvage radiation therapy in patients with prostate-specific antigen rise after radical prostatectomy","volume":"69","author":"Fossati","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2016.08.003_bib0830","doi-asserted-by":"crossref","first-page":"i851","DOI":"10.1136\/bmj.i851","article-title":"Second malignancies after radiotherapy for prostate cancer: systematic review and meta-analysis","volume":"352","author":"Wallis","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.eururo.2016.08.003_bib0835","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/S0167-8140(00)00306-6","article-title":"ESTRO\/EAU\/EORTC recommendations on permanent seed implantation for localized prostate cancer","volume":"57","author":"Ash","year":"2000","journal-title":"Radiother Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.eururo.2016.08.003_bib0840","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/j.1464-410X.2011.10827.x","article-title":"Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group","volume":"109","author":"Grimm","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2016.08.003_bib0845","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.eururo.2011.09.027","article-title":"Functional outcomes and complications following radiation therapy for prostate cancer: a critical analysis of the literature","volume":"61","author":"Bud\u00e4us","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2016.08.003_bib0880","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.brachy.2005.12.002","article-title":"Relationship of the International Prostate Symptom score with urinary flow studies, and catheterization rates following 125I prostate brachytherapy","volume":"5","author":"Martens","year":"2006","journal-title":"Brachytherapy"},{"key":"10.1016\/j.eururo.2016.08.003_bib0850","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1080\/02841860600710913","article-title":"3-D conformal treatment of prostate cancer to 74Gy vs. high-dose-rate brachytherapy boost: a cross-sectional quality-of-life survey","volume":"45","author":"Vordermark","year":"2006","journal-title":"Acta Oncol"},{"key":"10.1016\/j.eururo.2016.08.003_bib0855","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.radonc.2013.05.002","article-title":"GEC\/ESTRO recommendations on high dose rate afterloading brachytherapy for localised prostate cancer: an update","volume":"107","author":"Hoskin","year":"2013","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.eururo.2016.08.003_bib0860","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta19490","article-title":"Ablative therapy for people with localised prostate cancer: a systematic review and economic evaluation","volume":"19","author":"Ramsay","year":"2015","journal-title":"Health Technol Assess"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283816304705?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283816304705?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T00:06:38Z","timestamp":1718755598000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283816304705"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":89,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["S0302283816304705"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2016.08.003","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2017,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2016.08.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 European Association of Urology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}